Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)
35.70
+1.41 (4.11%)
Apr 15, 2026, 3:04 PM CST
SHE:002422 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 6,032 | 3,974 | 4,675 | 4,729 | 2,920 |
Short-Term Investments | 635.45 | 555.65 | 579.39 | - | - |
Trading Asset Securities | 1,457 | 1,921 | 1,691 | 448.11 | 359.53 |
Cash & Short-Term Investments | 8,124 | 6,451 | 6,946 | 5,177 | 3,279 |
Cash Growth | 25.95% | -7.13% | 34.17% | 57.88% | 7.96% |
Accounts Receivable | 6,007 | 6,098 | 6,120 | 7,198 | 6,463 |
Other Receivables | 82.69 | 126.17 | 162.49 | 256.3 | 221.92 |
Receivables | 6,090 | 6,224 | 6,283 | 7,454 | 6,685 |
Inventory | 3,847 | 3,801 | 3,840 | 3,214 | 3,363 |
Other Current Assets | 1,978 | 1,460 | 1,222 | 804.22 | 681.4 |
Total Current Assets | 20,040 | 17,936 | 18,290 | 16,649 | 14,009 |
Property, Plant & Equipment | 13,074 | 13,012 | 12,086 | 11,331 | 11,614 |
Long-Term Investments | 4,624 | 4,281 | 3,992 | 3,809 | 3,409 |
Goodwill | 96.25 | 98.66 | 98.66 | 98.66 | 98.66 |
Other Intangible Assets | 1,226 | 1,223 | 1,277 | 1,201 | 1,063 |
Long-Term Deferred Tax Assets | 455.25 | 423.03 | 342.57 | 618.21 | 581.57 |
Long-Term Deferred Charges | 90.87 | 83.06 | 75.72 | 233.81 | 365.28 |
Other Long-Term Assets | 228.74 | 260.11 | 293.17 | 264.34 | 400.05 |
Total Assets | 39,835 | 37,316 | 36,455 | 34,206 | 31,540 |
Accounts Payable | 2,533 | 2,574 | 2,539 | 2,244 | 2,156 |
Accrued Expenses | 1,964 | 2,259 | 2,028 | 1,973 | 1,610 |
Short-Term Debt | 3,261 | 2,457 | 3,458 | 4,499 | 5,183 |
Current Portion of Long-Term Debt | 151.15 | 808.4 | 746.86 | 2,012 | 3,199 |
Current Portion of Leases | 60.73 | 62.56 | 40.53 | 17.31 | 11.57 |
Current Income Taxes Payable | 125.74 | 140.11 | 162.74 | 108.18 | 119.48 |
Current Unearned Revenue | 563.13 | 645.45 | 839.83 | 360.36 | 264.69 |
Other Current Liabilities | 531.61 | 190.71 | 177.87 | 889.3 | 864.55 |
Total Current Liabilities | 9,190 | 9,138 | 9,993 | 12,104 | 13,408 |
Long-Term Debt | 191.1 | 342 | 2,649 | 4,704 | 3,506 |
Long-Term Leases | 544.46 | 537.46 | 245.23 | 51.74 | 16.18 |
Long-Term Unearned Revenue | 326.81 | 294.65 | 288.21 | 208.88 | 225.73 |
Long-Term Deferred Tax Liabilities | 285.2 | 266.09 | 264.1 | 265.83 | 254.32 |
Other Long-Term Liabilities | 3.74 | - | 0.08 | - | - |
Total Liabilities | 10,541 | 10,578 | 13,439 | 17,335 | 17,410 |
Common Stock | 1,598 | 1,601 | 1,499 | 1,422 | 1,425 |
Additional Paid-In Capital | 8,768 | 7,732 | 6,144 | 3,673 | 3,581 |
Retained Earnings | 13,924 | 13,222 | 11,973 | 10,416 | 9,328 |
Treasury Stock | -131.7 | -191.83 | -215.14 | -237.08 | -399.98 |
Comprehensive Income & Other | 66.39 | 115.84 | 272.07 | 459.82 | -77.49 |
Total Common Equity | 24,224 | 22,480 | 19,672 | 15,734 | 13,857 |
Minority Interest | 5,069 | 4,259 | 3,343 | 1,137 | 272.62 |
Shareholders' Equity | 29,294 | 26,738 | 23,016 | 16,871 | 14,129 |
Total Liabilities & Equity | 39,835 | 37,316 | 36,455 | 34,206 | 31,540 |
Total Debt | 4,208 | 4,207 | 7,139 | 11,285 | 11,916 |
Net Cash (Debt) | 3,916 | 2,243 | -193.52 | -6,108 | -8,637 |
Net Cash Growth | 74.58% | - | - | - | - |
Net Cash Per Share | 2.46 | 1.42 | -0.13 | -4.12 | -6.11 |
Filing Date Shares Outstanding | 1,590 | 1,591 | 1,488 | 1,412 | 1,406 |
Total Common Shares Outstanding | 1,590 | 1,591 | 1,488 | 1,412 | 1,406 |
Working Capital | 10,850 | 8,798 | 8,297 | 4,545 | 600.44 |
Book Value Per Share | 15.23 | 14.13 | 13.22 | 11.15 | 9.85 |
Tangible Book Value | 22,902 | 21,158 | 18,297 | 14,434 | 12,695 |
Tangible Book Value Per Share | 14.40 | 13.30 | 12.29 | 10.23 | 9.03 |
Buildings | 7,665 | 7,464 | 6,557 | 6,160 | 6,057 |
Machinery | 13,792 | 13,101 | 11,592 | 11,348 | 11,078 |
Construction In Progress | 1,504 | 1,204 | 2,045 | 1,126 | 922.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.